Piper Sandler Reiterates Overweight Rating on Abivax (ABVX) Following New IBD Surveys
Tweet Send to a Friend
Piper Sandler analyst Christopher J. Raymond reiterated an Overweight rating and $42.00 price target on Abivax (NASDAQ: ABVX).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
